NCT00693524View on ClinicalTrials.gov

Sequential Therapy (FK506 + Monoclonal Anti-IL2R Antibodies + MMF) Versus FK506 With Steroids in Liver TX

PHASE2CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

November 30, 2002

Primary Completion Date

March 31, 2004

Study Completion Date

March 31, 2004

Conditions
Liver Transplantation
Interventions
DRUG

tacrolimus

oral

DRUG

Anti-IL2R AB

i.v.

DRUG

Mycophenolate mofetil

oral

DRUG

prednisone

oral

Trial Locations (8)

Unknown

Bologna

Genova

Milan

Napoli

Padua

Roma

Torino

Udine

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY

NCT00693524 - Sequential Therapy (FK506 + Monoclonal Anti-IL2R Antibodies + MMF) Versus FK506 With Steroids in Liver TX | Biotech Hunter | Biotech Hunter